|
Jul 31
|
Chief Scientific Officer Patrick Soon-Shiong, ImmunityBio, Inc.'s (NASDAQ:IBRX) largest shareholder sees value of holdings go down 6.5% after recent drop
|
|
Jun 20
|
ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
|
|
May 17
|
Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
|
|
May 11
|
ImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
May 7
|
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
|
|
May 2
|
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
|
|
Apr 30
|
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
|
|
Apr 25
|
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
|
|
Apr 23
|
ImmunityBio's bladder cancer therapy wins FDA approval
|
|
Apr 23
|
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
|
|
Mar 6
|
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
|
|
Mar 5
|
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
|
|
Jan 2
|
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
|
|
Apr 25
|
National Multicenter Trial Opens to Study ImmunityBio’s Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome
|
|
Apr 25
|
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong Delivers the Packard Lecture at Uniformed Services University
|